William Richard White Sells 1,957 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White sold 1,957 shares of Disc Medicine stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $64.63, for a total transaction of $126,480.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

William Richard White also recently made the following trade(s):

• On Friday, November 1st, William Richard White sold 201 shares of Disc Medicine stock. The shares were sold at an average price of $46.37, for a total transaction of $9,320.37.
• On Monday, November 4th, William Richard White sold 7,136 shares of Disc Medicine stock. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96.
• On Tuesday, October 1st, William Richard White sold 201 shares of Disc Medicine stock. The stock was sold at an average price of $51.31, for a total transaction of $10,313.31.

Disc Medicine Price Performance

NASDAQ:IRON opened at $62.31 on Friday. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of -15.66 and a beta of 0.76. The company’s 50-day moving average is $55.07 and its two-hundred day moving average is $48.05. Disc Medicine, Inc. has a 1-year low of $25.60 and a 1-year high of $77.60.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.15. As a group, equities analysts anticipate that Disc Medicine, Inc. will post -4.05 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IRON has been the topic of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a research report on Tuesday, October 15th. Morgan Stanley upgraded shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price target on the stock in a research report on Tuesday, November 5th. Wedbush restated an “outperform” rating and set a $83.00 price target (up from $75.00) on shares of Disc Medicine in a research report on Tuesday, November 12th. HC Wainwright boosted their price target on shares of Disc Medicine from $70.00 to $118.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and boosted their price target for the stock from $66.00 to $110.00 in a research report on Monday, November 4th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Disc Medicine has a consensus rating of “Buy” and a consensus price target of $85.80.

Institutional Investors Weigh In On Disc Medicine

Institutional investors and hedge funds have recently made changes to their positions in the stock. Amalgamated Bank raised its stake in shares of Disc Medicine by 76.9% in the 2nd quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after acquiring an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Disc Medicine by 45.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after acquiring an additional 337 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Disc Medicine in the 2nd quarter valued at approximately $129,000. Quest Partners LLC purchased a new stake in shares of Disc Medicine in the 3rd quarter valued at approximately $131,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Disc Medicine in the 3rd quarter valued at approximately $146,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.